Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
Precision treatment in colorectal cancer: Now and the future - Yau - 2019 - JGH Open - Wiley Online Library
APMG Colon Molecular Pathways
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer | Oncogene
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies | Journal of Molecular Medicine
New combination therapy offers bowel cancer patients extra treatment option
Cancers | Free Full-Text | Targeting BRAF and RAS in Colorectal Cancer
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer
Mechanisms of resistance to EGFR inhibitors in colorectal cancers | Colorectal Cancer
Biomarkers in colorectal cancer: Current clinical utility and future perspectives
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
IJMS | Free Full-Text | Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer | Aging
![PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2e5f89dec8a25afc1d61dc3d7197afa33839845d/2-Figure1-1.png "PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar")
PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar
Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
![PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2e5f89dec8a25afc1d61dc3d7197afa33839845d/3-Figure2-1.png "PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar")
PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar
Biomarqueurs des cancers colorectaux utiles en pratique clinique – FMC-HGE
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
Different EGFR signalling pathways induced by the interaction between... | Download Scientific Diagram
Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab - Kim - 2020 - International Journal of Cancer - Wiley Online Library
Frontiers | Targeting EGFR in Esophagogastric Cancer
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
The Role of the Epidermal Growth Factor Receptor in the Mechanism and Treatment of Colorectal Cancer - Nirit Yarom - Discovery Medicine
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies | Journal of Molecular Medicine
